ENGN
NASDAQenGene Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News25/Ratings12
News · 26 weeks58-7%
2025-12-282026-06-21
Mix3190d
- Analyst10(32%)
- Insider8(26%)
- SEC Filings7(23%)
- Other4(13%)
- Earnings2(6%)
Latest news
25 items- SECAmendment: enGene Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update8-K/A - enGene Therapeutics Inc. (0001980845) (Filer)
- ANALYSTenGene Therapeutics downgraded by Morgan StanleyMorgan Stanley downgraded enGene Therapeutics from Equal-Weight to Underweight
- INSIDERSEC Form 4 filed by Director Astley-Sparke Philip4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Director Brunk Gerald A4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Director Glickman Richard M4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Interim Chief Medical Officer Grossman William4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Director Hastings Paul J4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Director Heffernan Michael Thomas4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Director Zoth Lota S.4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- INSIDERSEC Form 4 filed by Director Joustra Wouter4 - enGene Therapeutics Inc. (0001980845) (Issuer)
- SECSEC Form 10-Q filed by enGene Therapeutics Inc.10-Q - enGene Therapeutics Inc. (0001980845) (Filer)
- SECenGene Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - enGene Therapeutics Inc. (0001980845) (Filer)
- PRenGene Reports Second Quarter 2026 Financial Results and Provides Business Update12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focus on BLA and precommercial activities Well capitalized with cash, cash equivalents and marketable securities of $285 million enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and pr
- SECenGene Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - enGene Therapeutics Inc. (0001980845) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.SCHEDULE 13G/A - enGene Therapeutics Inc. (0001980845) (Subject)
- SECSEC Form SCHEDULE 13G filed by enGene Therapeutics Inc.SCHEDULE 13G - enGene Therapeutics Inc. (0001980845) (Subject)
- SECSEC Form DEF 14A filed by enGene Therapeutics Inc.DEF 14A - enGene Therapeutics Inc. (0001980845) (Filer)
- ANALYSTenGene Therapeutics downgraded by Raymond James with a new price targetRaymond James downgraded enGene Therapeutics from Strong Buy to Outperform and set a new price target of $4.00
- ANALYSTenGene Therapeutics downgraded by Piper Sandler with a new price targetPiper Sandler downgraded enGene Therapeutics from Overweight to Neutral and set a new price target of $4.00
- ANALYSTenGene Therapeutics downgraded by GuggenheimGuggenheim downgraded enGene Therapeutics from Buy to Neutral
- ANALYSTenGene Therapeutics downgraded by CitizensCitizens downgraded enGene Therapeutics from Mkt Outperform to Mkt Perform
- ANALYSTenGene Therapeutics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded enGene Therapeutics from Outperform to Market Perform and set a new price target of $2.00
- ANALYSTenGene Therapeutics downgraded by Wells Fargo with a new price targetWells Fargo downgraded enGene Therapeutics from Overweight to Equal Weight and set a new price target of $2.00
- ANALYSTenGene Therapeutics downgraded by Morgan StanleyMorgan Stanley downgraded enGene Therapeutics from Overweight to Equal-Weight
ENGN FAQ
5 questionsWhere does ENGN stock trade?
enGene Therapeutics Inc. (ENGN) is listed on NASDAQ.What sector and industry is ENGN in?
enGene Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ENGN?
enGene Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Underweight on 2026-06-18. Recent price targets range from $200.00 to $400.00.What companies are similar to ENGN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ENGN side-by-side with any of them on Quantisnow.How can I track ENGN on Quantisnow?
Quantisnow aggregates enGene Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENGN to receive live email and push alerts on every new disclosure.